Evidence map›Paper›PMID 39181964›Full record

ArticleScientific reports2024

MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer.

Fei Wang, Hua Shen, Kai Li, Yanhong Ding, Jianqing Wang, Jian Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinicogenomic Insights for Progression-Free Survival in Prostate Cancer.International journal of environmental research and public health · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fei Wang *Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China.
Hua Shen *Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China.
Kai LiDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China.
Yanhong DingDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China.
Jianqing WangDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China. jqwang14@fudan.edu.cn.
Jian SunDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 26 Daoqian Rd, Suzhou, 215000, Jiangsu, People's Republic of China. drsunjian1978@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PRAD) is one of the leading malignancies in men all around the world. Here, we identified Myosin Heavy Chain 6 (MYH6) as a potential tumor suppressor gene in the development of prostate cancer. We found lower expression of MYH6 in prostate cancer tissues, and its lower gene expression was also associated with worse clinical outcomes. In vitro and in vivo assays indicated that overexpressed MYH6 could suppress the proliferation and migration progression of prostate cancer cells. RNA-seq was employed to investigate the mechanism, and KIT Proto-Oncogen (KIT) was determined as the downstream gene of MYH6, which was further confirmed using rescue assays. In all, we provide the evidence that MYH6 could serve as a tumor suppressor in prostate cancer. Our results highlight the potential role of MYH6 in the development of prostate cancer.

Indexed as

Cell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticMyosin Heavy ChainsProstatic NeoplasmsProto-Oncogene Proteins c-kitAnimalsCardiac MyosinsCell Line, TumorDown-RegulationHumansMaleMiceCardiac MyosinsMYH6 protein, humanMyosin Heavy ChainsProto-Oncogene Proteins c-kitMYH6Prognostic markerProstate cancerTumor suppressor gene

Identifiers

PMID39181964
PMCPMC11344859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.